Osteoporotic Precisely Screening Using Chest Radiograph and Artificial Neural Network (OPSCAN)

Osteoporosis Clinical Trial

Official title:

Osteoporotic Precisely Screening Using Chest Radiograph and Artificial Neural Network (OPSCAN): a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05721157
• Other study ID #: NDMC2023001
• Status: Completed
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: June 30, 2023

Study information

• Verified date: July 2023
• Source: National Defense Medical Center, Taiwan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Artificial Intelligence-assisted Diagnosis and Prognostication in Osteoporosis Using Chest X-ray

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4912
• Est. completion date: June 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients recieved at least 1 chest X-ray examination in 2022

• More than 66% chest X-ray identified as high risk of osteoporosis by AI-CXR

Exclusion Criteria:

• Patients with history of at least 1 dual energy x-ray absorptiometry (DXA)

• Patients with history of osteoporosis or osteoportic fracture

• Patients recieved prescription anti-osteoporotic treatment (excluding vitamin D or calcium)

• Patients died before 01 Jan 2023

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporotic Fractures

Intervention

Other:
• AI-enabled Chest X-ray-based Screening Tool
Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.

Locations

Country	Name	City	State
Taiwan	Tri-service general hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Defense Medical Center, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	newly diagnosed with osteoporosis	After performing an chest X-ray, the osteoporosis was followed.	Within 180 days
Secondary	initiation of DXA examination	After performing an chest X-ray, the osteoporosis was followed.	Within 180 days
Secondary	initiation of anti-osteoporotic treatment	After performing an chest X-ray, the osteoporosis was followed.	Within 180 days